Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N9 in High-Risk Neuroblastoma
NCT04947501Phase 1Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2021
- Primary completion
- Jun 2027
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Targeted Liposomes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cyclophosphamide, topotecan liposome, vincristine sulfate liposome injection, pegylated liposomal doxorubicin, ifosfamide and 3 more in neuroblastoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Safety of the N9 regimen through toxicity assessment at 16 weeks. Started Jun 2021; status: active, not recruiting.
02
Drugs
cyclophosphamidetopotecan liposomevincristine sulfate liposome injectionpegylated liposomal doxorubicinifosfamide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04947501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04947501.